Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Status:
Not yet recruiting
Trial end date:
2032-02-01
Target enrollment:
Participant gender:
Summary
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone
(fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of
children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are
unable to receive additional anthracyclines, or in 2nd relapse.
Phase:
Phase 3
Details
Lead Sponsor:
LLS PedAL Initiative, LLC
Collaborators:
AbbVie EuPAL Princess Maxima Center for Pediatric Oncology (European Sponsor) Roche-Genentech